Free Trial
OTCMKTS:FSNUY

Fresenius SE & Co. Q1 2026 Earnings Results & Report

Fresenius SE & Co. logo
$14.83 +0.11 (+0.77%)
As of 10:57 AM Eastern

Fresenius SE & Co. missed analyst expectations on both earnings and revenue in its Q1 2026 results, released May 6, 2026. The company reported EPS of $0.24 versus the $0.2535 consensus estimate, while revenue of $6.75 billion fell short of the $6.79 billion estimate by $36.92 million.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens

Fresenius SE & Co. EPS Results

Actual EPS
$0.24
Consensus EPS
$0.2535
Beat/Miss
Missed by -$0.0135
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 6 quarters

Fresenius SE & Co. Revenue Results

Actual Revenue
$6.75 billion
Expected Revenue
$6.79 billion
Beat/Miss
Missed by -$36.92 million
YoY Revenue Growth
N/A

Conference Call Resources

Fresenius SE & Co. Q1 2026 Earnings FAQ

Fresenius SE & Co. (OTCMKTS:FSNUY) reported earnings of $0.24 per share for Q1 2026, missing the consensus estimate of $0.2535. The report was announced on Wednesday, May 6, 2026.

Fresenius SE & Co. reported revenue of $6.75 billion for Q1 2026, against a consensus estimate of $6.79 billion.

Fresenius SE & Co. Earnings Headlines

Fresenius plans to sell around 13.4 million FMC shares
A Bill Would Reprice America's Gold at Market Value
The US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,000 today, leaving a trillion-dollar gap on the books. A bill now moving through Congress would require the Treasury to reprice America's gold at true market value. Companion legislation would trigger the first full audit of US reserves in over 65 years.tc pixel
Jefferies leaves Fresenius SE at 'Buy', target €55
See More Fresenius SE & Co. Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fresenius SE & Co.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fresenius SE & Co. and other key companies, straight to your email.

About Fresenius SE & Co.

Fresenius SE & Co. (OTCMKTS:FSNUY) KGaA is a German healthcare group headquartered in Bad Homburg. Its businesses include Fresenius Kabi, which supplies medicines, clinical nutrition, infusion therapies and medical technologies, and Fresenius Helios, which operates hospitals in Germany and Spain.

Fresenius Kabi serves healthcare providers around the world, while Helios focuses on hospital and healthcare services in Europe. The group traces its origins to a pharmacy in Frankfurt acquired by pharmacist Eduard Fresenius in 1912.

Michael Sen has served as Fresenius’s chief executive officer since 2022. Through its businesses, the company provides products and services across areas including hospital care, pharmaceuticals and medical technology.

View Fresenius SE & Co. Profile